# Moderna raises 2026 outlook on strong vaccine momentum

> Moderna beat earnings estimates and raised full-year guidance as newer vaccines gain traction in international markets.
- Title: Moderna raises 2026 outlook on strong vaccine momentum · CNBC
- Summary: Moderna beat earnings estimates and raised full-year guidance as newer vaccines gain traction in international markets.
- Keywords: moderna, mrna, earnings, covid vaccine, flu vaccine, revenue guidance, biotech, CNBC
- Source: CNBC — https://cnbc.com/2026/11/06/moderna-mrna-earnings-q3-2026.html
- Author: Annika Kim Constantino
- Published: 2026-11-06T11:47:42+00:00
- Read time: 1 min
- Topics: moderna, mrna, earnings, covid vaccine, flu vaccine, revenue guidance, biotech, business, finance
## Moderna beats estimates, raises outlook
Moderna smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth as newer products gain momentum.
## New guidance: fifteen to twenty-five percent growth
The biotech company now expects two thousand twenty-six revenue growth of fifteen percent to twenty-five percent, up from its previous guidance of up to ten percent.
## CEO credits new products and geography
Moderna CEO Stéphane Bancel said new product launches and the diversification of geography drove the strong third quarter performance.

> The new product and the diversification of geography is what has led to such a strong Q3
## Q3 results beat Wall Street expectations
Moderna reported earnings per share of thirty-eight cents versus an expected loss of one dollar twenty-five, and revenue of one point three one billion dollars versus eight hundred eighty-five point one million dollars expected.
## New vaccines drive international revenue growth
Third-quarter revenue jumped twenty-nine percent to one point three one billion dollars, boosted by higher Covid vaccine sales in international markets and long-term government partnerships.
## Key takeaway

Moderna beat third-quarter estimates and raised 2026 revenue growth guidance to fifteen to twenty-five percent from up to ten percent, citing new product launches and geographic diversification.